Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) - P/B ratio
P/B ratio as of May 2024 : 7.70
According to Adaptimmune Therapeutics's latest financial reports the company has a price-to-book ratio of 7.70.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Adaptimmune Therapeutics - P/B ratio (from 2015 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 4.56 | 56.03% |
| 2022-12-31 | 2.92 | 2.72% |
| 2021-12-31 | 2.84 | 16.32% |
| 2020-12-31 | 2.45 | 139.54% |
| 2019-12-31 | 1.02 | -58.09% |
| 2018-12-31 | 2.44 | -21% |
| 2017-12-31 | 3.08 | 78.68% |
| 2016-12-31 | 1.73 | -49.33% |
| 2015-12-31 | 3.41 | |
| 2014-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 uniQure QURE | 1.09 | -85.80% | 🇳🇱 Netherlands |
 Novavax NVAX | -0.9224 | -111.98% | 🇺🇸 USA |
 Exelixis EXEL | 2.85 | -63.02% | 🇺🇸 USA |
 Enzo Biochem ENZ | 0.7527 | -90.22% | 🇺🇸 USA |